Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Incyte Corporation
Related studies linked through entity extraction aliases.
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
- Status
- COMPLETED
- Phase
- PHASE3
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Ruxolitinib to Combat COVID-19
- Status
- WITHDRAWN
- Phase
- PHASE2
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
- Status
- WITHDRAWN
- Phase
- PHASE3
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
- Status
- TERMINATED
- Phase
- PHASE2
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Baricitinib in Participants With Rheumatoid Arthritis
- Status
- COMPLETED
- Phase
- PHASE4
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
- Status
- TERMINATED
- Phase
- PHASE1